Critical analysis and US patent landscape: US 8,202,517
US 8,202,517 claims methods to enhance delivery of a co-administered drug or biologic by administering a specifically defined neutral-active hyaluronidase glycoprotein (with defined sequence windows, optional substitutions with ≥95% identity, and at least one N-linked sugar moiety on an asparagine residue). The core claim 1 is a broad platform delivery method that covers multiple classes of therapeutic cargoes (small molecules and proteins), multiple administration schedules and sites, and production and formulation variants (mammalian expression, optional polymer modification, PEG/dextran, and unit ranges).
What does claim 1 actually protect?
Claim 1 is a two-part method:
- Administer hyaluronidase glycoprotein
- Sequence definition: the hyaluronidase glycoprotein consists of amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO: 1; or contains amino-acid substitutions in those sequence windows while still being ≥95% amino acid sequence identity with those windows.
- Functional/chemical constraints:
- Neutral active (neutral pH activity characterization).
- Contains at least one sugar moiety covalently attached to an asparagine (N) residue of the polypeptide (i.e., glycosylation).
- Dose constraint (later claims): administered in an amount that is or is between 1 and 10,000 Units/mL (claim 21).
- Administer a therapeutically effective amount of a drug/pharmaceutical agent
- Cargo can be a small molecule or a protein (claim 2).
- Claim 3 enumerates a broad menu of therapeutic categories.
Claim 1 scope in plain terms
This is not limited to any one therapeutic or indication. It is a delivery enhancer claim tied to a specific hyaluronidase glycoprotein identity (sequence window + neutral activity + N-linked glycosylation) and then an open-ended list of drugs, including proteins like antibodies and cytokines.
The dependent claims: where the patent narrows and where it stays broad
What cargo classes are explicitly covered (claims 2-9, 28)?
-
Claim 2: drug is selected from small molecule and protein.
-
Claim 3: enumerates classes ranging from chemotherapeutics and analgesics to antibiotics/antifungals, cardiovascular agents, hormones, diagnostics, vitamins, CNS drugs, etc.
-
Claims 4-9 add examples:
- Chemotherapeutic agent is a toxin or tumor necrosis factor (claim 4).
- Anesthetic agent is lidocaine or bupivacaine (claim 5).
- Insulin (claim 6).
- Cytokine (claim 7).
- Antibody or antibody fragment (claim 8).
- Monoclonal antibody (claim 9).
-
Claim 28: drug is “therapeutic agent” (adds no practical narrowing beyond claim 1 but keeps the claim from being argued as non-therapeutic).
Landscape implication: The enumeration of classes is broad enough that most “use hyaluronidase to increase delivery of an administered drug” strategies are captured, provided the hyaluronidase identity requirements in claim 1 are met.
What administration mechanics are claimed (claims 10-13, 22-27)?
-
Co-therapy option:
- Claim 10: further comprising administering a hormonal agent.
- Claim 11: hormonal agent is epinephrine.
- Claim 12: hormonal agent administered simultaneously or sequentially with hyaluronidase glycoprotein.
-
Scheduling/placement:
- Claim 22: hyaluronidase and molecule provided in same or separate compositions.
- Claim 23: hyaluronidase administered prior to, simultaneously with, or following administration of the molecule.
- Claim 24: hyaluronidase administered at site different from molecule.
- Claim 25: same site.
- Claim 26-27: parenteral administration includes subcutaneous, intravenous, intramuscular.
Landscape implication: These dependent claims help neutralize design-around arguments based on formulation separation, timing, and anatomical site.
What hyaluronidase identity and variants are claimed (claims 13-21)?
- Claim 13 repeats the core sequence variant list exactly.
- Claim 14 and 15 specify:
- claim 14: composition with sequence amino acids 36-482 of SEQ ID NO:1
- claim 15: substitution variants with ≥95% identity to any of the listed windows
- Claim 19: hyaluronidase modified with a polymer.
- Claim 20: polymer is PEG or dextran.
- Claim 21: dose range 1 to 10,000 Units/mL.
Landscape implication: Design-around options that simply use a different formulation (separate carrier, different timing) are covered. Substitutions and polymer modifications are also covered, which expands the defensible “near-neighbor” space around the specified hyaluronidase.
What manufacturing and expression specifics are claimed (claims 16-18)?
- Claim 16: hyaluronidase produced and secreted from a mammalian cell using an expression vector with a polynucleotide containing nucleotides 106-1446 of SEQ ID NO:6 (or degenerates) or SEQ ID NO:48 (or degenerates), inserted between flanking sequences.
- Claim 17: polynucleotide has SEQ ID NO:48.
- Claim 18: mammalian cell is CHO.
Landscape implication: This is a valuable narrowing lever if infringement turns on manufacturing source or vector sequence, but it also provides a roadmap for valid production. It does not fully limit the claim set since claim 1 does not require the particular production method; dependent claims do.
Claim coverage map: what an accused product would need to do to infringe
A prima facie infringement posture (conceptually) requires satisfying:
A) Hyaluronidase glycoprotein identity
- Neutral-active hyaluronidase glycoprotein.
- Sequence window requirement: amino acids 36-477 through 36-483 (or substitutions) with ≥95% identity to those windows.
- N-linked glycosylation: at least one covalently attached sugar moiety to an asparagine residue.
B) Co-administration mechanics
- Deliver “therapeutically effective amount” of a drug/pharmaceutical agent (broad list in dependent claims).
- Parenteral route supported (subQ/IV/IM).
- Timing, site, and whether separate compositions are allowed are all covered.
C) Optional add-ons
- Polymer modification (PEG/dextran) and dose range are specifically claimed in dependent claims.
- Hormonal agent (epinephrine) is explicitly claimed in dependent claims.
Critical validity and patentability pressure points
Even without file-history details provided here, claim structure creates predictable legal and technical stress points:
1) Broad “function-first” delivery claim tied to a specific protein identity
The claim blends:
- biological identity constraints (sequence windows, neutral activity, N-linked glycosylation), and
- broad therapeutic use (many drug classes, timing/site variations).
That structure can be vulnerable if prior art shows:
- a hyaluronidase with similar sequence identity and glycosylation,
- used as a delivery enhancer across many therapeutic classes,
- under similar administration and scheduling.
If an earlier patent or publication discloses essentially the same hyaluronidase construct (or one that is within the “≥95% identity” envelope) and uses it to increase delivery of drugs broadly, claim 1 could be attacked under novelty and obviousness.
2) The ≥95% identity threshold expands the claim to “near variants”
The identity clause reduces the patentee’s dependence on an exact sequence. It also increases prior art risk: an earlier glycoprotein that is highly similar on the relevant region can map into the claim even if it is framed differently in the art.
Practically, that often shifts the fight to:
- alignment boundaries (do prior sequences include the same 36-x region?),
- how many substitutions exist,
- and whether the prior art product is “neutral active” and “glycosylated at N.”
3) “Neutral active” and glycosylation are plausible discriminators but fact-dependent
Those two requirements can distinguish prior art, but they create evidentiary burden:
- If prior art describes “hyaluronidase” without establishing neutral pH activity and glycoprotein glycosylation status, an argument can be made that claim elements are not met.
- If prior art does include neutral-active and glycosylated hyaluronidase, those are strong infringement hooks and weak validity defenses.
4) Dependent claims enumerate common therapeutic categories
The breadth in claim 3 makes it harder to argue a narrow unexpected utility, unless the specification provides a specific mechanism or surprising effect for multiple categories. Otherwise, the claim reads like a standard delivery-enhancement method with a fixed excipient.
Technical claim construction risks and design-around analysis
What are the likely design-around strategies?
Given the tight identity requirements for the hyaluronidase glycoprotein, the most direct design-around is to change at least one of:
- the relevant amino-acid window (36-477 through 36-483),
- the “≥95% identity” mapping to that window,
- neutral pH enzymatic activity profile,
- or the glycosylation requirement (N-linked sugar moieties).
Switching administration route (e.g., oral) may avoid some dependent claims (subQ/IV/IM), but claim 1 does not limit route. Timing and site are covered by claims 22-25.
Polymer modification (PEG/dextran) is optional in dependent claim 19-20, so avoiding polymer modification only helps if those dependent claims are asserted; it likely does not avoid claim 1.
How much do the dependent claims matter in practice?
- If asserted against a commercial hyaluronidase formulation or a biologic co-administration protocol, claim 1 is the main battleground.
- Claims 21 (dose range) and 19-20 (polymer) are relevant when product labeling or formulation matches those dependent parameters.
- Claims 16-18 (mammalian cell/CHO/vector) can become critical if infringement depends on showing the specific engineered construct, but most litigations for method-of-use patents focus on the delivered product and its identity rather than vector provenance.
Competitive positioning: what the claims imply about the platform
The patent reads like a platform around a defined engineered hyaluronidase glycoprotein:
- Cargo-agnostic: broad drug lists.
- Formulation-adaptive: polymer modification and separate or same compositions.
- Operationally flexible: schedule and site options; parenteral routes included.
- Manufacturing scaffolding: mammalian expression and optional CHO production with defined nucleotides.
This supports licensing and cross-asset defense for any therapy paired with this hyaluronidase construct.
Usability of the claims against the real-world hyaluronidase ecosystem
The global commercial landscape includes multiple hyaluronidase products (varying sources and formulations). The claims here are not “hyaluronidase per se.” They require:
- neutral-active hyaluronidase glycoprotein with defined sequence windows,
- with N-linked glycosylation.
So generic hyaluronidase products that are not neutral-active glycoprotein variants within the identity thresholds may fall outside. Conversely, engineered glycosylated neutral-active hyaluronidase variants with high identity to the specified region are more likely to be captured.
Key “landscape” takeaway: the claim is engineered-protein-centric, not disease-centric
US 8,202,517 is best characterized as an engineered hyaluronidase delivery enhancer patent:
- disease/indication coverage is effectively unlimited,
- but the protein identity is the gating factor.
That means:
- Clearance risk concentrates where competitors use the same or highly similar neutral-active glycosylated hyaluronidase constructs.
- Freedom-to-operate for drug developers depends less on which therapeutic class they use and more on whether their co-administered hyaluronidase matches the claim-defined sequence, glycosylation, and activity properties.
Key Takeaways
- US 8,202,517 claim 1 protects a method-of-enhanced delivery using a neutral-active hyaluronidase glycoprotein defined by specific amino-acid windows (36-477 through 36-483 of SEQ ID NO:1), allowing substitutions with ≥95% identity, and requiring N-linked glycosylation.
- Dependent claims keep the method broad across small molecules and proteins and across many drug categories, while covering timing, site, and same vs separate compositions, and parenteral routes (subQ/IV/IM).
- The most practical design-around lever is to change the hyaluronidase identity elements (sequence identity, neutral activity, or N-linked glycosylation). Changing schedule or formulation logistics alone is unlikely to avoid claim 1.
- Validity pressure likely concentrates on whether prior art discloses a high-identity neutral-active glycosylated hyaluronidase used as a delivery enhancer across multiple therapeutic cargos.
FAQs
1) Is US 8,202,517 limited to a single therapeutic or indication?
No. Claim 1 is not indication-limited and claim 3 enumerates many therapeutic categories; the method is cargo-agnostic as long as the therapeutic is a “drug or pharmaceutical agent” administered therapeutically effectively.
2) What is the single most important element to assess for infringement?
The accused hyaluronidase glycoprotein identity: neutral-active enzymatic activity, the defined SEQ ID NO:1 amino-acid window (36-477 to 36-483) with substitutions allowed only if the variant has ≥95% identity, and presence of at least one N-linked sugar moiety.
3) Do the dependent claims narrow the method-of-use to specific administration timing?
They broaden timing. Claims 23 and 24-25 explicitly cover hyaluronidase administered before, simultaneously with, or after the drug, and at the same or different site.
4) Does polymer modification matter?
Polymer modification (PEG or dextran) is claimed in dependent claims (19-20). It can be relevant if asserted, but claim 1 does not require polymer modification.
5) Can competitors avoid risk by using separate compositions for hyaluronidase and drug?
The patent covers both combined and separate compositions (claim 22), so separation alone is not a reliable design-around for claim 1.
References
- US Patent Application/Patent text for US 8,202,517 (claims as provided in the prompt).
